PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16732565

Multiscale modelling methodology for virtual prototyping of effervescent tablets.

Frantisek Stepanek·Adeline Loo·Tiong Shing Lim
View original source ↗Export metadata ↓

Abstract

Computational methodology for virtual tablet prototyping has been developed. The methodology consists of two steps: construction of virtual particle compacts of varying composition using the discrete element method (DEM), and the simulation of their dissolution by eroding individual components from the tablet microstructure according to their intrinsic dissolution rates, using the volume-of-fluid (VOF) method. The effective erosion rate obtained from simulations at the particle assembly length-scale is used for the calculation of dissolution time at the tablet length-scale. The methodology is demonstrated on the case of a simple effervescent formulation consisting of sodium bicarbonate-acetic acid effervescent system, sodium chloride as a model active substance, and lactose filler. The experimentally measured dependence of tablet dissolution time on composition and compaction force was found to be in very good agreement with outputs from computer simulations.

Explore related subjects

Citric AcidComputer SimulationKineticsLactoseModels, ChemicalSodium BicarbonateSodium ChlorideSolubilityTabletsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Frantisek Stepanek, Adeline Loo, Tiong Shing Lim. 2006. Multiscale modelling methodology for virtual prototyping of effervescent tablets.. https://doi.org/10.1002/jps.20624

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

OBJECTIVES: To examine whether the time between blood drawing and centrifugation (TBDC) affects the levels of matrix metalloproteinase (MMP)-9 and MMP-2 levels in serum and in plasma samples, and to assess whether there is correlation between MMP-9 and MMP-2 levels in serum and plasma samples. DESIGN AND METHODS: Serum and plasma samples (N=8) were separated from venous blood collected into citrate, heparin, and EDTA tubes, which were either centrifuged immediately or after 5, 10, 20, or 30 min after blood drawing. We assessed the correlation between MMP-9/MMP-2 in serum and citrate, heparin, and plasma samples (N=20), which were assayed for gelatine zymography of MMP-2 and MMP-9. RESULTS: MMPs are released by platelets or leukocytes during platelet activation or sampling process, thus leading to artificially higher MMP-9 levels in serum compared with citrate, heparin, or EDTA plasma samples, independently of TBDC. Citrate and heparin plasma samples had the lowest Pro-MMP-9 and MMP-9 levels, which correlated with each other. Pro-MMP-9 levels in serum correlated with Pro-MMP-9 levels in EDTA or citrate plasma, but not with heparin plasma. While no significant correlations were found between MMP-9 levels in serum and those found in plasma samples, the total MMP-9 levels (Pro-MMP-9+MMP-9) in serum and in plasma samples correlated with each other. No significant differences were found in pro-MMP-2 levels. CONCLUSIONS: These results suggest that the circulating levels of MMP-9 should be assessed in citrate or heparin plasma samples, but not in serum samples because of artificially higher MMP-9 levels in serum, independently of TBDC, and because they do not correlate with the MMP-9 levels in plasma samples.

Citric Acid↗
PubMed2006

Extraction of heavy metals from municipal solid waste incinerator (MSWI) bottom ash with organic solutions.

Municipal solid waste incinerator (MSWI) bottom ash often cannot be recycled as construction material in Flanders, because leaching of Cu exceeds the limit value of 0.5mg/kg. Leaching of other components such as Mo and Sb is critical as well, but limit values for these elements are to date only informal. A treatment technique was investigated to lower pollutant leaching: extraction with solutions of organic complexants to remove Cu. Six different solutions were used, of which washing with citric acid and ammonium citrate decreases Cu leaching to below the limit value. Extraction was then performed with different concentrations of ammonium citrate. Subsequent washing of the extracted material with distilled water appears to be vital to remove all residual ammonium citrate. Extraction with a 0.2M solution of ammonium citrate followed by three washing steps decreases metal leaching to below the limit values.

Citric Acid↗
PubMed2006

Does citrate prevent nephrocalcinosis in preterm neonates?

Nephrocalcinosis (NC) occurs frequently in preterm neonates. A high U-calcium/citrate is one of the contributing factors to the development of NC. In stone-forming children and adults citrate supplementation is a successful preventive therapy. In this randomized controlled trial the effect of citrate therapy was studied on the development of NC in preterm neonates with a gestational age <32 weeks. Thirty-eight preterm neonates (mean gestational age 29.8 weeks (SD 1.6), mean birth weight 1,300 g (SD 351) were treated with sodium citrate (0.52 mmol/kg/day in four doses) from day 8 of life until at term and 36 preterm neonates (mean gestational age 29.6 weeks (SD 1.6), mean birth weight 1,282 g (SD 256) were not treated. U-calcium, U-creatinine, U-citrate and U-pH were measured at day 7, 14, 21, 28 of life and at term. Renal ultrasonography (US) was performed at term. U-citrate/creatinine and U-pH were significantly higher and U-calcium/citrate was significantly lower in the citrate group at day 14, 21 and 28 compared with the control group (P<0.05). Complications of citrate administration were not encountered, however the incidence of NC was not significantly different in the treated (34%) compared with the control group (44%), P=0.37. Preterm neonates treated with citrate in the first months of life have higher U-citrate/creatinine and lower U-calcium/citrate compared with controls. Sodium citrate therapy in a dosage of 0.52 mmol/kg/day is safe but does not prevent NC. Whether a higher dose or potassium citrate decreases the incidence of NC should be evaluated in further studies.

Citric Acid↗